Answers are grounded in this paper and cite their sources.
This study aimed to evaluate the type, frequency, onset, and recovery duration of neurological symptoms caused by COVID-19, including newly emerging post-COVID-19 neurological findings, to contribute to improved prognosis and follow-up strategies. A total of 110 COVID-19 patients hospitalized with positive SARS-CoV-2 PCR tests (24 December 2021–10 March 2022) were prospectively assessed. Neurological symptoms during hospitalization and at 1, 3, and 6 months post-discharge were documented, with all findings confirmed by a neurologist. The time of symptom onset was recorded for each patient. Fatigue (75.5%) was the most common symptom, lasting 10.43 weeks on average, followed by myalgia (57.3%, 4.29 weeks) and headache (56.4%, 3.35 weeks). Forgetfulness persisted the longest (22.03 weeks). Headache and myalgia were more frequent in women, while symptoms like dizziness, insomnia, and nausea/vomiting were more common in patients aged ≤50. No significant differences in symptom duration were observed based on age or gender. Neurological symptoms, such as fatigue, headache, myalgia, and forgetfulness, were prevalent in both the acute and post-COVID-19 phases. The study underscores the importance of systematic neurological monitoring and the development of individualized follow-up strategies to manage long-term neurological effects and improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Bulğak et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: